Elizabeth Brém

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Raphael Koch, Amanda L. Christie, Jennifer L. Crombie et al. · Blood · 2018 · 59 citations · Full text

Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas

Elizabeth Brém, Karen E. Thudium, Sapna Khubchandani et al. · British Journal of Haematology · 2011 · 52 citations · Full text

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study

Bradley M. Haverkos, Önder Alpdoğan, Robert A. Baiocchi et al. · Blood Advances · 2023 · 38 citations · Full text

Immunology, Pathology, Pharmacotherapy +21

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV +) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

Bradley M. Haverkos, Önder Alpdoğan, Robert A. Baiocchi et al. · Blood · 2021 · 24 citations

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool

Elizabeth Brém, Hongli Li, Anne Beaven et al. · Journal of Geriatric Oncology · 2021 · 22 citations · Full text